Ito Yasuo, Sugimoto Yoshihisa, Tomioka Masao, Kai Nobuo, Tanaka Masato
Department of Orthopaedic Surgery, Kobe Red Cross Hospital, Kobe, Japan.
Spine (Phila Pa 1976). 2009 Sep 15;34(20):2121-4. doi: 10.1097/BRS.0b013e3181b613c7.
Consecutive cohort study.
To reconsider effects of the Second National Acute Spinal Cord Injury Study.
High dose methylprednisolone sodium succinate (MPSS) for the patients with acute spinal cord injury has been considered standard treatment in the several countries. However, many authors have criticized the effect of MPSS because of lack of evidence about neurologic improvement and the high incidence of complications.
During 2-year, all patients with cervical cord injury were treated with MPSS within 8 hours of their injuries based on the Second National Acute Spinal Cord Injury Study protocol (MPSS group). During the next 2-year, all patients were treated without MPSS (non-MPSS group). There were 38 patients in the MPSS group and 41 in the non-MPSS. Early spinal decompression and stabilization was performed as soon after injury in both the groups.
According to The American Spinal Injury Association (ASIA) motor score, there was an average improvement by 3 months postinjury of 12.4 points in the MPSS group and 13.8 points in the non-MPSS group. In patients with complete motor loss, average ASIA motor score improved 9.0 points in the MPSS group and 12.6 points in the non-MPSS group. For patients with incomplete motor loss, average ASIA motor score improvement was 14.1 and 15.5 points in the MPSS and non-MPSS groups, respectively.In the MPSS group, 19 patients developed pneumonia, 13 developed urinary tract infections, and 5 developed wound infections. Incidence of pneumonia was significantly increased with the use of MPSS medication.
We found no evidence supporting the opinion that high-dose MPSS administration facilitates neurologic improvement in patients with spinal cord injury. We believe MPSS should be used under limited circumstances because of the high incidence of pulmonary complication.
连续队列研究。
重新审视第二次全国急性脊髓损伤研究的效果。
在多个国家,大剂量琥珀酸钠甲泼尼龙(MPSS)用于急性脊髓损伤患者已被视为标准治疗方法。然而,许多作者批评MPSS的效果,因为缺乏神经功能改善的证据以及并发症发生率高。
在两年期间,根据第二次全国急性脊髓损伤研究方案,所有颈髓损伤患者在受伤后8小时内接受MPSS治疗(MPSS组)。在接下来的两年中,所有患者未接受MPSS治疗(非MPSS组)。MPSS组有38例患者,非MPSS组有41例患者。两组均在受伤后尽早进行早期脊柱减压和固定。
根据美国脊髓损伤协会(ASIA)运动评分,MPSS组伤后3个月平均提高12.4分,非MPSS组提高13.8分。在完全运动丧失的患者中,MPSS组ASIA运动评分平均提高9.0分,非MPSS组提高12.6分。对于不完全运动丧失的患者,MPSS组和非MPSS组ASIA运动评分平均提高分别为14.1分和15.5分。在MPSS组中,19例患者发生肺炎,13例发生尿路感染,5例发生伤口感染。使用MPSS药物后肺炎发生率显著增加。
我们没有发现证据支持大剂量使用MPSS能促进脊髓损伤患者神经功能改善的观点。由于肺部并发症发生率高,我们认为MPSS应在有限的情况下使用。